Anavex Life Sciences (STU:12X1) ROCE % : -48.42% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Anavex Life Sciences's annualized ROCE % for the quarter that ended in Dec. 2024 was -48.42%.

Anavex Life Sciences ROCE % Historical Data

The historical data trend for Anavex Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences ROCE % Chart

Anavex Life Sciences Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

ROCE %

Get a 7-Day Free Trial

-126.44

-42.29

-35.35

-31.50

-32.12

Anavex Life Sciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-32.45	-30.93	-37.30	-36.98	-48.42

Anavex Life Sciences ROCE % Calculation

Anavex Life Sciences's annualized ROCE % for the fiscal year that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2024 )		(A: Sep. 2023 )		(A: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2024 )		(A: Sep. 2023 )		(A: Sep. 2024 )
	=	-38.745	/	( ( (144.66 - 11.744)	+	(122.146 - 13.789) )	/ 2 )
	=	-38.745	/	( (132.916	+	108.357)	/ 2 )
	=	-38.745	/	120.6365
	=	-32.12 %

Anavex Life Sciences's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-51.876	/	( ( (122.146 - 13.789)	+	(118.461 - 12.537) )	/ 2 )
	=	-51.876	/	( ( 108.357	+	105.924 )	/ 2 )
	=	-51.876	/	107.1405
	=	-48.42 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Anavex Life Sciences (STU:12X1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Anavex Life Sciences ROCE % Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Anavex Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

AVXL:USA 0HFR:UK 12X1:Germany

Address

630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Anavex Life Sciences Headlines

No Headlines